Olutasidenib in Combination with Azacitidine Induces Durable Complete Remissions in Patients with Relapsed or Refractory Midh1 Acute Myeloid Leukemia: a Multicohort Open-Label Phase 1/2 Trial
Journal of Hematology & Oncology（2025）
关键词
Isocitrate dehydrogenase-1,Hypomethylating agent,Mutant IDH1 inhibitor,Relapsed,Refractory,AML,Combination therapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要